Psmb5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@ciechanover2015]
Overview
PSMB5 (Proteasome Subunit Beta Type 5) encodes the β5 subunit of the 20S proteasome, which possesses the primary chymotrypsin-like proteolytic activity responsible for cleaving hydrophobic residues. This catalytic subunit is the main proteolytic engine of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and its dysfunction is critically implicated in the pathogenesis of major neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). PSMB5 is essential for neuronal [protein homeostasis](/mechanisms/protein-quality-control-network) and the clearance of pathological protein aggregates. [@nguyen2021]
Psmb5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@ciechanover2015]
Overview
PSMB5 (Proteasome Subunit Beta Type 5) encodes the β5 subunit of the 20S proteasome, which possesses the primary chymotrypsin-like proteolytic activity responsible for cleaving hydrophobic residues. This catalytic subunit is the main proteolytic engine of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and its dysfunction is critically implicated in the pathogenesis of major neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). PSMB5 is essential for neuronal [protein homeostasis](/mechanisms/protein-quality-control-network) and the clearance of pathological protein aggregates. [@nguyen2021]
| Property | Value | [@tai2008] |----------|-------| [@dantuma2010] | Protein Name | Proteasome Subunit Beta Type 5 | | Gene | [PSMB5](/genes/psmb5) | | UniProt ID | [P28074](https://www.uniprot.org/uniprot/P28074) | | PDB ID | [5MX3](https://www.ebi.ac.uk/pdbe/5MX3) | | Molecular Weight | 28.5 kDa | | Subcellular Localization | Cytoplasm, Nucleus | | Protein Family | Proteasome beta subunit family | | Catalytic Activity | Chymotrypsin-like (primary) |
</div>
Structure
The PSMB5 protein is a 262-amino acid subunit containing the N-terminal threonine catalytic residue (Thr1). It adopts the classic α/β fold of proteasome subunits.
Catalytic Core
PSMB5 provides the majority of proteasome proteolytic activity:
Chymotrypsin-like specificity: Cleaves after large hydrophobic residues (Phe, Leu, Trp, Tyr)
iPSC neurons from neurodegenerative disease patients
Animal Models
PSMB5 conditional knockout mice
Transgenic models with proteasome impairment
AAV-mediated PSMB5 overexpression
Biomarkers
Proteasome Activity
Fluorogenic substrate assays (Suc-LLVY-AMC)
CSF proteasome levels as disease marker
Blood proteasome in neurodegenerative diseases
Background
The study of Psmb5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[PubMed: PSMB5 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PSMB5+neurodegeneration) — Literature search
References
[Groll M, et al., Structure of the 20S proteasome at 2.4 Å resolution. Nature. 1997;386(6624):463-471 (1997)](https://doi.org/10.1038/386463a0))
[Unknown, Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8(8):739-758 (2001)](https://doi.org/10.1016/s1074-5521(01))
[Thibaudeau TA, et al., Proteasome as a therapeutic target in neurodegenerative disease. Curr Pharm Des. 2013;19(18):3260-3274 (2013)](https://pubmed.ncbi.nlm.nih.gov/23431944/))
[Unknown, Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases. Exp Mol Med. 2015;47:e147 (2015)](https://doi.org/10.1038/emm.2014.117))
[Nguyen P, et al., Proteasome modulation as a therapeutic approach in Alzheimer's disease. Front Aging Neurosci. 2021;13:630853 (2021)](https://doi.org/10.3389/fnagi.2021.630853))
[Zhang J, et al., Alpha-synuclein and proteasome in Parkinson's disease. J Neural Transm (Vienna). 2018;125(3):461-472 (2018)](https://doi.org/10.1007/s00702-017-1730-9))
[Unknown, Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal diseases. Nat Rev Neurosci. 2008;9(11):826-838 (2008)](https://doi.org/10.1038/nrn2499))
[Unknown, Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases. J Alzheimers Dis. 2010;20(1):S131-S146 (2010)](https://doi.org/10.3233/JAD-2010-100666))